Noxopharm (ASX:NOX) - CEO, Dr Graham Kelly
CEO, Dr Graham Kelly
Source: Switzer Financial Group [Youtube]
Market Herald logo


Be the first with the news that moves the market
  • Noxopharm (NOX) has applied for an international patent to use its clinical-stage drug, Veyonda, to treat septic shock
  • Pre-clinical data has shown Veyonda’s ability to block the cytokine storm that leads to septic shock and causes blood clots, organ damage and even death
  • Septic shock occurs when people have an excessive immune response after suffering a bacterial infection or virus such as COVID-19
  • Currently, there’s a lack of effective treatment options for septic shock, which presents Noxopharm with a significant commercial opportunity
  • Company shares are up 3.97 per cent to trade at 65.5 cents

Noxopharm (NOX) has lodged an international patent application for the extended use of Veyonda in treating septic shock.

Veyonda is a clinical-stage drug aimed at providing better treatment options for cancer patients.

One of its anti-cancer actions is blocking a signalling pathway, called STING, which triggers an immune response and the repair of damaged tissue. However, some people suffer an excessive STING response which is what causes septic shock.

In particular, septic shock occurs in response to infections from viruses, such as COVID-19 and influenza, and a wide range of bacterial infections and parasites, such as malaria.

The septic shock process involves pro-inflammatory chemicals, known as cytokines, being released into the blood which can cause clotting and lead to organ damage and death.

Due to their being a lack of effective treatments, septic shock is reportedly responsible for around 10 million deaths per year as well as a further three million deaths from COVID-19. This presents a significant commercial opportunity.

While there are some supportive treatments for septic shock, there’s an unmet need for reducing cytokine levels. For example, trials to date have shown COVID-19 patients who’ve been administered with drugs to block individual cytokines have either failed or have only been moderately effective.

Veyonda’s aim is to block the production of multiple cytokines and pre-clinical data has shown its main active ingredient, idronoxil, is likely to do so.

Noxopharm is currently testing blood samples of patients from its NOXCOVID trial which tested Veyonda’s potential to stop COVID-19 from worsening into cytokine release syndrome (CRS) and septic shock. Results will be reported in the upcoming weeks.

Company shares are up 3.97 per cent to trade at 65.5 cents at 11:20 am AEST.

NOX by the numbers
More From The Market Herald
Argenica Therapeutics (ASX:AGN) - CEO, Dr Liz Dallimore

" Argenica Therapeutics (ASX:AGN) determines safe starting dose level for ARG-007

Argenica Therapeutics (ASX:AGN) determines safe starting dose level from toxicology and genotoxicity studies
Arovella Therapeutics (ASX:ALA) - CEO and Managing Director, Dr Michael Baker

" Arovella Therapeutics (ASX:ALA) to raise $6m for cell therapies

Arovella Therapeutics (ASX:ALA) has received firm commitments from institutional and sophisticated investors for a $4.57 million…

" Radiopharm Theranostics (ASX:RAD) acquires IP ownership of Radiopharmaceutical Nanobodies

Radiopharm Theranostics (ASX:RAD) acquires full intellectual property (IP) ownership to three assets from NanoMab Technology.
Nuheara (ASX:NUH) - CEO, Justin Miller

" Nuheara (ASX:NUH) completes $1.06m SPP

Hearing technology company Nuheara (ASX:NUH) has completed its share purchase plan (SPP) with applications totalling $1,067,200.